C2N Gains More than $7 Million Funding Toward Development Of Alzheimer’s Disease Testing Solution 

C2N Diagnostics received an investment of up to $7.03 million from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator initiative. ;It will use the funding toward its efforts to;develop biomarkers and novel diagnostic technologies that aid in the early detection and diagnosis of Alzheimer’s and clinical trial design.;

C2N’s Precivity blood tests are used to help diagnose Alzheimer’s disease. It aims to create a fully automated, standardized, high resolution liquid chromatography-mass spectrometry (LC-MS) platform to enable the local deployment of the innovation in clinical labs around the world . . .